New Genentech drug to treat source of blindness

06/29/2006 | NYTimes.com

The FDA this week is expected to clear for marketing Genentech's Lucentis for treating wet macular degeneration, a major cause of blindness in people over 65. Some doctors currently prescribe another Genentech drug, Avastin, off label to treat the condition, but Lucentis is being described as a breakthrough by specialists because it is the first drug that has been shown in clinical trials to improve vision.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL